News.

We’re thrilled to announce our participation at #BioEquityEurope 2024!
Robert Thong, our CEO at MultiOmic Health, will be presenting on our innovative approach to tackle cardiorenal complications. Join us for insights into how we aim to transform the landscape of metabolic syndrome through precision medicine.

Read more

MultiOmic Health, an artificial intelligence (AI)-enabled drug discovery company, is embarking on a collaborative project with the Centre for Public Health at Queen’s University Belfast (QUB) in Northern Ireland to develop data-driven diagnostic tools for Diabetic Kidney Disease (DKD).

Read more

What insight can recent trials give us into how molecular-level disease drivers can be used to enter into a new era of precision nephrology?

Read more

MultiOmic Health has closed a £5 million seed extension round to build its precision therapeutics discovery platform for metabolic syndrome.

Read more

MultiOmic Health forges research collaboration with Northern Care Alliance NHS Foundation Trust in diabetic kidney disease

Read more

MultiOmic is proud to announce winning first place in the pitch competition at BIA’s TechBio UK Conference 2022

Read more

In this article, we look at how Mesh Bio and MultiOmic Health use AI to transform and improve the lives of metabolic syndrome patients through patient stratification and precision medicine.

Read more

An Expert View from Henrietta Bull, science and partnership analyst, and Robert Thong, chief executive, MultiOmic Health.

Read more

In this week’s episode of The Pharma Letter Podcast, MultiOmic chief executive Robert Thong discusses his firm’s progress and ambitions for the future.

Read more

MultiOmic Health and Mesh Bio announce their partnership to conduct an observational clinical study on patients with chronic metabolic disease.

Read more

10/11